Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019

Safiri, Saeid; Sohrabi, Mohammad‐Reza; Carson‐Chahhoud, Kristin; Bettampadi, Deepti; Taghizadieh, Ali; Almasi‐Hashiani, Amir; Ashrafi‐Asgarabad, Ahad; Sepidarkish, Mahdi; Eagen, Arielle; Mansournia, Mohammad Ali; Kolahi, Ali‐Asghar

doi:10.1016/j.jtho.2021.03.030

Cited by 29 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding how specific exposures are contributing to morbidity and mortality patterns over time in subgroups of the global population is therefore essential to targeting preventive measures. As previously discussed, recent studies have described TBL burden in the GBD 2017 and GBD 2019 data, but either lack the use of the most recent GBD 2019 data or lack sufficiently robust analysis to identify statistically significant subpopulation trends for tobacco, APMP, or HAP exposures [ 9 , 10 , 11 , 12 ]. Much has remained consistent between the GBD 2017 and GBD 2019, including the methodology of modeling tobacco exposure-outcome pairs and broad trends in tobacco, APMP, and HAP-attributable TBL mortality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterizing Trends in Lung Cancer Mortality Attributable to Airborne Environmental Carcinogens

Veith

McAlarney

Xue

et al. 2021

IJERPH

View full text Add to dashboard Cite

Tracheal, bronchus, and lung (TBL) cancer is the leading cause of cancer death globally, but trends in TBL mortality attributable to tobacco, ambient particulate matter pollution (APMP), and household air pollution (HAP) were unequally distributed within global population subgroups over the last three decades. We used data from the Global Burden of Disease 2019 study to quantify the impact of sex, time, sociodemographic development index (SDI), and age for each exposure from 1990–2019. During that interval, tobacco dominated the TBL cancer mortality landscape, with its minimum global age-adjusted death rate of 16.71 deaths/100,000 (95% Uncertainty Interval (UI): 15.27–18.13) outstripping maximums of 3.85 deaths/100,000 (UI: 2.82–4.83) and 2.54 deaths/100,000 (UI: 1.69–3.54) for APMP and HAP, respectively. In 2019, tobacco male TBL death rates exceeded female rates by a factor of 4.4:1. Ratios of 1.9:1 for APMP and 2.1:1 for HAP were seen. Our analysis indicates that both-sex middle SDI and female low, low-middle, and high-middle SDI populations are suffering increasing tobacco TBL burden. Efforts producing successful global reductions in HAP-associated TBL mortality should continue, with attention to low SDI female death rate increases. Finally, except for high SDI populations, global APMP-attributable TBL cancer burden is increasing and represents a major health concern.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recent studies have shed light on TBL incidence, DALYs, and mortality trends in the GBD 2017 and GBD 2019 data [ 9 , 10 , 11 , 12 ]. Wang et al and Deng et al described the dynamic temporal trends in TBL cancer burden across SDI, sex, and age group in GBD 2017 data.…”

Section: Introductionmentioning

confidence: 99%

Characterizing Trends in Lung Cancer Mortality Attributable to Airborne Environmental Carcinogens

Veith

McAlarney

Xue

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Aging is a major problem facing mankind, and the pursuit of immortality is an eternal topic [111][112][113][114]. After more and more studies, mesenchymal stem cells have been found to play a great role in combating aging.…”

Section: The Anti-aging Effect Of Mscsmentioning

confidence: 99%

Mesenchymal stem cells: ideal seeds for treating diseases

Gao

Fan

et al. 2021

Human Cell

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), a kind of multipotent stem cells with self-renewal ability and multi-differentiation ability, have become the "practical stem cells" for the treatment of diseases. MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn's disease. MSCs also can be used in cancer and aging. At present, many clinical experiments are using MSCs. MSCs can reduce the occurrence of inflammation and apoptosis of tissue cells, and promote the proliferation of endogenous tissue and organ cells, so as to achieve the effect of repairing tissue and organs. MSCs presumably also play an important role in Corona Virus Disease 2019 (COVID-19) infection. Keywords Mesenchymal stem cells • Autoimmune diseases • Aging • Inflammation • Cancer • COVID-19 Abbreviations AA Alginate ARDS Acute respiratory distress syndrome BM-MSCs Bone marrow mesenchymal stem cells BMP-2 Bone morphogenetic protein 2 CBX4 Chromobox protein homologue 4 CRISPR Clustered Regularly Interspaced Short Palindromic Repeats Cas9 CRISPR-associated protein-9 nuclease Col Collagen COPD Chronic obstructive pulmonary disease COVID-19 Corona Virus Disease 2019 CRC Colorectal cancer CXCR7 C-X-C chemokine receptor type 7 CXCL12 C-X-C motif chemokine ligand 12

show abstract

“…Lung cancer remains the leading cause of cancer-related mortality worldwide ( 1 , 2 ). Many studies have shown that the incidence rate of lung cancer in non-smoking women and the detection rate of lung cancer, especially lung adenocarcinoma, after the implementation of lung cancer screening program are both increasing year by year, and lung adenocarcinoma has become the most common subtype of lung cancer and has the highest gene mutation rate ( 3 - 8 ).…”

Section: Introductionmentioning

confidence: 99%

Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects

Ma¹,

Li²

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Objective The purpose of this paper was to perform a narrative review of current research evidence on conventional computed tomography (CT) imaging features and CT image-based radiomic features for predicting gene mutations in lung adenocarcinoma and discuss how to translate the research findings to guide future practice. Background Lung cancer, especially lung adenocarcinoma, is the leading cause of cancer-related deaths. With advances in the diagnosis and treatment of lung adenocarcinoma with the emergence of molecular testing, the prediction of oncogenes and even drug resistance gene mutations have become key to individualized and precise clinical treatment in order to prolong survival and improve quality of life. The progress of imageological examination includes the development of CT and radiomics are promising quantitative methods for predicting different gene mutations in lung adenocarcinoma, especially common mutations, such as epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) mutation and Kirsten rat sarcoma viral oncogene (KRAS) mutation. Methods The PubMed electronic database was searched along with a set of terms specific to lung adenocarcinoma, radiomics (including texture analysis), CT, computed tomography, EGFR, ALK, KRAS, rearranging transfection (RET) rearrangement and c-ros oncogene 1 (ROS-1), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and human epidermal growth factor receptor 2 (HER2) mutations et al. This review has been reported in compliance with the Narrative Review checklist guidelines. From each full-text article, information was extracted regarding a set of terms above. Conclusions Research on the application of conventional CT features and CT image-based radiomic features for predicting the gene mutation status of lung adenocarcinoma is still in a preliminary stage. Noninvasively determination of mutation status in lung adenocarcinoma before targeted therapy with conventional CT features and CT image-based radiomic features remains both hopes and challenges. Before radiomics could be applied in clinical practice, more work needs to be done.

show abstract

Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019

Cited by 29 publications

References 20 publications

Characterizing Trends in Lung Cancer Mortality Attributable to Airborne Environmental Carcinogens

Characterizing Trends in Lung Cancer Mortality Attributable to Airborne Environmental Carcinogens

Mesenchymal stem cells: ideal seeds for treating diseases

Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects

Contact Info

Product

Resources

About